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The major immediate-early promoter (MIEP) of human cytomegalovirus (HCMV) constitutes a primary
genetic switch for viral activation. In this study, regulation of the enhancer-containing segment (nucleotides
2670 to 154) of the HCMV MIEP attached to the lacZ reporter gene was examined in the developing embryos
of transgenic mice to identify temporal and tissue-specific expression. We find that the transgene reporter is
first detected as a dorsal stripe of expression in the neural folds of embryos at day 8.5 postcoitum (p.c.). A
broad expression pattern is exhibited in embryos at day 9.5 p.c. This pattern becomes more restricted by day
10.5 p.c. as organogenesis progresses. By day 14.5 p.c., prominent expression is observed in a subpopulation
of central nervous system cells and spinal ganglia, endothelial cells, muscle, skin, thyroid, parathyroid, kidney,
lung, liver, and gut cells, and the pancreas and submandibular and pituitary glands. This distribution pattern
is discussed in relation to human congenital HCMV infection. These results suggest that the transcriptional
activity of the HCMVMIEP may determine in part, the ability of the virus to specifically target developing fetal
tissues in utero.
Human cytomegalovirus (HCMV) infects most humans by
adulthood and is a significant cause of morbidity and mortality
for individuals in the clinical setting, particularly cancer pa-
tients, neonates, and patients with AIDS (18, 39). HCMV is
also considered to be one of the leading causes of congenital
infection in humans, affecting 40,000 children annually in the
United States alone (15, 30). Approximately 20% of these
children are born with some form of irreversible brain damage,
resulting in various degrees of mental retardation and pro-
found deafness (16, 36).
The host and viral factors that determine sites of infection
and progression to disease in congenital HCMV infection are
not known. For most DNA viruses, cell type (tissue) tropism is
determined by three key types of virus-cell interaction. The
initial tissue-selective interaction involves the attachment and
penetration of cells by virus. HCMV is capable of entering
many different cell types in vitro and in vivo (e.g., see refer-
ences 25 and 29 and references therein), indicating that this
initial interaction step is unlikely to be a major determinant for
its tropism. The second type of virus-cell interaction, which is
perhaps the most significant for HCMV, depends on appro-
priate levels of host-encoded transcription and/or replication
factors (reviewed in references 12 and 26). In vivo, immune
surveillance by the host provides the third determining tier of
tropism. In this case, immune clearance would be expected to
play a more prominent role in the adult than in the embryo.
Thus, of these types of interactions, transcriptional regulation
of the viral major immediate-early promoter (MIEP) consti-
tutes a primary level by which this virus may determine tissue-
specific expression and activation state in the host. Therefore,
we are interested in the role that cellular and viral factors play
in coordinating transcription from the MIEP. The MIEP is
highly dependent on cellular transcription factors for activity
and is composed of multiple domains, including promoter-
proximal downstream elements, a highly complex enhancer
domain, and various upstream modularity elements (12). The
majority of these regulatory elements are clustered between
nucleotide positions 2670 and 154 which, for the most part,
encompass the enhancer domain. Importantly, this enhancer-
containing segment of the MIEP has recently been shown to be
regulated in a tissue-specific fashion in adult transgenic mice,
recapitulating in part the natural HCMV infection pattern in
humans (4). Moreover, a recent transgenic study by Koedood
et al. (23) using partial MIEP sequences located between nu-
cleotides 2525 and 113 [MIEP(2525/113)] suggests a similar
relationship may occur during fetal development. The trans-
genic mouse model, therefore, supports the prediction that
optimal MIEP activity is a critical determinant in the outcome
of a productive HCMV infection.
In this study, the MIEP transgenic mice serve as a paradigm
for investigating the developmental expression of the MIEP.
We present evidence that the MIEP enhancer-containing seg-
ment located between nucleotides 2670 and 154 [MIEP
(2670/154)] confers both temporal and spatial control of ex-
pression on the MIEP during embryogenesis. These results
complement and extend the recent MIEP transgenic embryo
report by Koedood et al. (23). A comparison of our data with
the spatiotemporal map developed by their MIEP(2525/113)
transgenic embryo system (23) reveals a number of new and
significantly different findings that most likely relate to the
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additional sequences located at nucleotide positions 2670 to
2525 and 113 to 154 of the MIEP used in this study. Taken
together, the observed expression patterns show many parallels
with tissues that are likely to be infected in utero in humans,
suggesting that the MIEP enhancer domain is an important
determinant in directing developmental expression of HCMV.
MATERIALS AND METHODS
Fixation and staining of whole embryos for b-galactosidase activity. The
generation and identification of the transgenic lines used in this study are de-
scribed elsewhere (4). Analysis of expression was performed on fetuses obtained
by mating hemizygous transgenic animals with outbred CD-1 mice. By this
means, each set of embryos produced contained approximately the expected
proportion of transgenic (50%) and wild-type (50%) genotypes, thus providing
internal controls to ensure that none of the staining was due to endogenous
mammalian b-galactosidase. Pregnant females were sacrificed at various stages
of pregnancy from 7.5 through 15.5 days postcoitum (p.c.). The middle of the day
after identification of the fertilization plug was designated as day 0.5 of gestation.
Embryos were obtained by dissecting conceptuses directly from the decidua in
cold phosphate-buffered saline (PBS) (2, 19); they were rapidly fixed in either
0.2% glutaraldehyde or 4% paraformaldehyde in PBS at 48C for 15 to 90 min,
rinsed, and then stained in X-Gal (5-bromo-4-chloro-3-indolyl-b-galactoside) at
378C (13). In addition, day 10.5 and 11.5 p.c. embryos were stained in haloge-
nated indolyl-b-galactoside (Bluo-gal) at 378C for b-galactosidase activity. De-
pending on the stage of development, blue staining was apparent between 30 min
and 6 h. Whole-mount embryos were photographed through a Wild-Leitz (M3Z)
stereo microscope.
Histochemical analysis.Histochemical staining for b-galactosidase activity was
performed on cryostat sections of (13.5 to 15.5 day p.c.) embryos stained with
X-Gal. Briefly, the embryos (fixed in 4% paraformaldehyde and stored in 30%
sucrose in PBS) were frozen in 30% sucrose. Twenty-micrometer-thick frozen
sections were cut and poststained with X-Gal overnight at 48C. Slides were rinsed
in Tris (pH 7.5), counterstained briefly with eosin, and dehydrated through
graded isopropyl alcohol. After brief immersion in xylene, the slides were cov-
erslipped with permount and examined under a light microscope. Day 10.5 and
11.5 p.c. embryos stained with Bluo-gal were postfixed in 4% paraformaldehyde
and dehydrated through graded ethanol solutions, cleared with methyl salicylate,
and embedded in paraffin; then 6-mm-thick sections were cut. After being depar-
affinized in xylene and hydrated in water, sections were counterstained briefly
with eosin and dehydrated through graded isopropyl alcohol. After brief immer-
sion in xylene, slides were coverslipped with permount and examined under a
Ziess axioplan microscope and photographed using an Olympus photomicros-
copy system.
It should be noted that the textual description of the expression patterns at
various stages of development is an account of all of our observations. Photo-
graphs have been selected to illustrate the points made in the text.
RESULTS
Embryonic expression of the HCMV MIEP enhancer-con-
taining transgene. A preliminary test for transgene expression
was performed by staining day 10.5 p.c. embryos, produced
from three previously characterized transgenic lines, for b-ga-
lactosidase activity (4). A schematic of the transgene construct
is shown in Fig. 1. Animals from each line produced litters
containing the expected 50% positive for the transgene, with
essentially identical and very specific patterns of expression.
Expression patterns were confirmed at all developmental
stages in the embryos of the three independent lines.
Transgene expression was first detected in day 8.5 p.c. head
fold-stage embryos (Fig. 2A and B). This expression coincided
with the end of gastrulation and the beginning of neuralation.
lacZ stain was observed mainly at the site of formation of the
head folds, demarcating the neural plates. This indicates a
rapid onset of transgene expression in late gastrulating em-
bryos, coinciding with formation of the neural plate.
FIG. 1. Schematic of the construct used to generate MIEP-lacZ transgenic
mouse lines. MIEP-lacZ contains a truncated version of the MIEP(2670/154),
lacking the modulator and NF1 regions, cloned upstream of the lacZ coding
sequence. It also contains 238 nucleotides of simian virus 40 poly(A) sequence
(nucleotides 2533 to 2770).
FIG. 2. Whole-mount staining of embryos with (A, C, E, G, and I) or without (B, D, F, H, and J) the MIEP-lacZ transgene. (A and B) Day 8.5 p.c. embryos.
Magnification, 320. (C and D) Day 9.5 p.c. embryos. Magnification, 315 and 316, respectively. (E and F) Day 11.5 p.c. embryos. Magnification, 310 and 38,
respectively. (G and H) Day 13.5 p.c. embryos. Magnification, 36.5. (I and J) Day 15.5 p.c. embryos. Magnification, 36.5.
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FIG. 3. Day 10.5 p.c. embryo. (A) Cross-section through the fore and hindbrain of a 10.5 day p.c. transgenic embryo. Enclosed areas are shown enlarged in the
respective panels. Bar, 500 mm. (B) Enlargement of area B, showing b-galactosidase-positive cells in the telencephalon (te) and diencephalon (di). Bar, 200 mm. (C)
Enlargement of area C, showing positive meningial cells (mn) near the telencephalon (te) and some faint staining near the pial surface of the telencephalon. Bar, 50
mm. (D) Enlargement of area D, showing trigeminal ganglion (V) and adjacent anterior cardinal vein (cv), with positive nerve cells (p) and positive endothelial cells
in small blood vessels (bv). Bar, 100 mm. (E) Enlargement of area E, showing Rathke’s pouch (rp) negative with positive blood vessels (bv) surrounding the
diencephalon (di) as well as positive cells in the diencephalon. Bar, 100 mm. (F) Enlargement of area F, showing the otic vesicle (ov) and vestibulocochlear ganglion
(VIII), with b-galactosidase-positive cells (arrows). Arrowhead indicates positive cells in the inner ear epithelium. Bar, 50 mm.
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By day 9.5 p.c., a broad staining pattern was observed in the
olfactory placode, branchial arches (first and second), all blood
vessels, somites, the maxillary process, cardiohepatic emi-
nence, and forelimb buds (Fig. 2C and D). Staining was also
observed in the central nervous system and in various sensory
ganglia, including the trigeminal, vestibulocochlear, nodose,
and dorsal root ganglia. The broad expression pattern indicates
a possible activation of transgene transcription in somatic and
neural tissues.
By days 10.5 and 11.5 p.c., expression of the transgene be-
came more restricted and began to show sharp tissue-specific
variation as organogenesis progressed. Strong staining was ob-
served in the region of the fourth ventricle of the hindbrain, as
well as in the somites, maxillary process, and blood vessels,
especially the branchial arch artery originating from the heart
(Fig. 2, compare panels E and F).
Examination of intact stained embryos at days 13.5 through
15.5 p.c. revealed specific surface staining in the skin, blood
vessels, vibrissa rudiment (whiskers), and around the eye and
auditory opening (Fig. 2, compare panels G with H and I with
J, respectively). We conclude from these results that the MIEP
of HCMV is functional during embryogenesis. Moreover,
these observations indicate that transcriptional activation of
the MIEP first occurs during the process of establishing the
basic body plan, after which expression becomes restricted to
specific sites of tissue differentiation.
To identify more precisely the spatial distribution of trans-
gene expression during organogenesis, serial sections of fetuses
from days 10.5 through 14.5 p.c. were prepared and examined
for lacZ expression.
Days 10.5 to 11.5 p.c. embryos.Day 10.5 p.c. embryo sections
showed transgene expression restricted to specific cell types
throughout the head and body regions. Frontal sections
showed strong staining of cells in the diencephalon of the brain
(Fig. 3A and B; Fig. 4G). Immediately outside the brain, in-
tense staining was developed in the meningial cell layer at the
diencephalon and telencephalon regions (Fig. 3C). Note, in
Fig. 4G very few meningial cells appear positive; however,
examination of serial sections of this embryo clearly showed
meningial staining (data not shown), indicating a restricted
subpopulation of cells in the meninges that express the trans-
gene. Weaker staining was observed near the pial surface of
the telencephalon (Fig. 3C). Transgene expression was also
detected in a subpopulation of nerve cells in the developing
brain and spinal cord as well as in the trigeminal ganglion (Fig.
3D), vestibulocochlear ganglion (Fig. 3F), and dorsal root gan-
glia (Fig. 5C). In addition, there was a striking layer of expres-
sion in the region of the developing cerebellum corresponding
to the choroid plexus anlagen (Fig. 6A and B; day 14.5 p.c.).
Otic vesicles associated with the third branchial arch and sclera
of the eye were also positive.
Prominent lacZ activity was also observed in the body of day
10.5 and 11.5 p.c. embryos. Staining was observed in the
somites, in part, colocalized to the myotomal compartment
which harbors the myogenic precursor cells. Consistent with
this observation subpopulations of skeletal muscle cells were
stained in day 13.5 and 15.5 p.c. embryos (data not shown).
Proliferating germinal matrix cells and neuronal cells of the
spinal cord also exhibited transgene expression (Fig. 4A to C;
Fig. 5). Embryo capillary and arterial endothelial cells were
heavily stained, including the aorta and the carotid and pul-
monary arteries (Fig. 4D, E, H, and I; Fig. 3; Fig. 5B and D to
F) and placental vascular endothelial cells (Fig. 7). Other tis-
sues which showed a subpopulation of cells positive for expres-
sion in day 10.5 and 11.5 p.c. embryos were the germinal ridges,
intracoetonic cavity, unidentified blood cells, and the heart
region, including the truncus, epicardium, and myocardium.
Day 14.5 p.c. embryos. By day 14.5 p.c., epithelial cells have
already begun to differentiate (such as the epithelia located in
the oral cavity, the esophagus, wall of the stomach, whisker
follicles, and glandular epithelium) and the first ossification
centers have appeared. Significant transgene expression was
detected in the olfactory and buccal epithelium (Fig. 6C and
D), the lining of the tongue (as well as striated muscle of the
tongue) (Fig. 6E), the tooth primordium (Fig. 6F), the lining of
the stomach and epithelium of the whisker follicles (data not
shown), pulmonary epithelial cells (Fig. 6G), and chondrocytes
in the ribs (Fig. 6I).
By day 14.5 p.c., Rathke’s pouch has fused with the dience-
phalic infundibulum, forming the anterior pituitary anlagen
from its epithelium. Although the Rathke’s pouch in day 11.5
p.c. embryos was negative for transgene expression (Fig. 3E),
strong staining of cells was observed in the intermediate and
anterior pituitary lobes (Fig. 6D) at day 14.5 p.c. Strong trans-
gene expression was also observed in all three layers of skin,
the peridermal, epidermal, and dermal layers (data not shown).
Other organ systems showing intensely stained subpopulations
of cells included the pancreas (Fig. 6P), lung (Fig. 6G), skeletal
muscle (data not shown), liver (Fig. 6O), kidney (Fig. 6N),
blood cells (Fig. 6K), thyroid and parathyroid glands (Fig. 6H),
and adrenal glands (Fig. 6M).
A summary of transgene expression in differentiating organs
at different developmental stages is shown in Table 1.
Transgene expression in extraembryonic structures. Al-
though expression was not observed in day 7.5 p.c. primitive
streak stage embryos, strong transgene expression was ob-
served at this time in cells corresponding to the precursor
placental cells of the ectoplacental cone (Fig. 7B). As embry-
onic development progresses, cells of the ectoplacental cone
become associated with the chorion, allantois, and endome-
trium to form the placenta. At these later stages of develop-
ment, the placenta was negative for staining; however, the
umbilical vein endothelium was highly positive for transgene
expression. (Fig. 7A). Other extraembryonic tissues showing
strong expression were the yolk sac (Fig. 7D), which regulates
the fluid volume of the amniotic cavity and serves as a nutritive
organ for the developing embryo, and a subpopulation of cells
in the amnion compartment (Fig. 7C), which provides thermal
and physical insulation for the fetus and causes the progressive
uterine distension necessary for normal uterine, placental, and
fetal development. Evidence of transgene activity at these sites
suggests that HCMV could potentially interfere with normal
FIG. 4. Day 10.5 p.c. embryo. (A) Cross-section of 10.5 day p.c. transgenic embryo sectioned at the dorsal aorta region. Boxes indicate areas enlarged in panels B
through E, respectively. Bar, 120 mm. (B) Spinal cord (sc) with b-galactosidase-positive staining in the neural motor column (arrows), as well as staining of small blood
vessels (bv) outside of the central nervous system. Bar, 50 mm. (C) Spinal cord (sc), b-galactosidase-positive neuronal cell (arrow), proliferating germinal matrix cells
(p), and endothelial cells of a small blood vessel (bv). Bar, 50 mm. (D) Portions of the dorsal aorta (da) and cardinal vein (cv), showing b-galactosidase-positive
endothelial cells (et). Bar, 50 mm. (E) Portions of the dorsal aorta (da) and dorsal mesentery (dm) with b-galactosidase-positive endoderm cells (ed) and possible
neuronal cells (arrows). Bar, 50 mm. (F) Cross-section through the head region. Box indicates approximate area enlarged in panel G. Bar, 250 mm. (G) b-galactosidase-
positive cells in the diencephalon (di) but not in the telencephalon (te). Positive endothelial staining of blood vessels (bv). os, optic stalk. Bar, 120mm. (H) Cross-section through
the fourth branchial arch (ba4). Note the positive endothelial cells (et) in the aortic arch 4 (aa4) and dorsal aorta (da). Nodose ganglion of the vagus nerve (3) is negative.
Bar, 50 mm. (I) Positive endothelial cells (et) in the heart truncus arteriosis (ta) and atrium (at) and myocardial cells (mc) in the atrioventricular canal (av). Bar, 50mm.
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fetal development by disrupting the function of these extraem-
bryonic structures.
DISCUSSION
We report here the expression pattern of a lacZ transgene
under the control of the HCMV enhancer-containing domain
[MIEP(2670/154)] during mouse embryogenesis from days
7.5 to 15.5 p.c.. The developmental pattern of expression me-
diated by the MIEP-lacZ transgene suggests that the enhancer
domain is involved in determining spatiotemporal control of
MIEP expression during early morphogenic events and in the
differentiation of various organ systems.
HCMV has been detected in a variety of organs, including
brain, spinal cord, peripheral ganglia, eye, ear, alimentary tract,
lung, liver, pancreas, kidney, heart, muscle, blood, endothe-
lium, gonads, pituitary, salivary, adrenal, and thyroid glands,
bone, tooth (epithelium), and skin (5, 14, 17, 18, 21, 22, 30, 31,
36, 37). HCMV infection in these various organ systems is
predominantly associated with epithelium-derived cells, al-
FIG. 5. Day 11.5 p.c. embryos. (A) Cross-section at the thoracic (abdominal) region of a 11.5 day p.c. transgenic embryo. Enclosed areas are shown enlarged in the
respective panels. Bar, 500 mm. (B) Enlargement of area B, showing a plexus of blood vessels (bv) in the limb, with positive endothelial cells. Bar, 100 mm. (C)
Enlargement of area C, showing spinal cord (sc) with b-galactosidase-positive cells in blood vessels (bv), meninges (mn), and dorsal root ganglion (drg). Bar, 100 mm.
(D) Enlargement of area D, showing a portion of the spinal cord (sc) with a positive neuronal cell (p) and positive neuronal cells in blood vessels (bv). drg, dorsal root
ganglia. Bar, 50 mm. (E) Enlargement of area E, showing positive endothelial cells in blood vessels (bv) and mesenchymal cells of the dorsal mesentery (dm) but lacking
positive cells in the lung bud (lb). gr, germinal ridge. Bar, 100 mm. (F) Enlargement of area F, showing b-galactosidase-positive endoderm cells (ed) at the level of the
forelimb bud, positive cells in the dorsal mesentery (dm), and endothelial cells in the vitellin vein (vv). Bar, 100 mm.
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though muscle, bone, blood, and endothelium may also be
infected. In parallel, we find that MIEP-driven expression in
transgenic embryos overlaps with these sites of natural infec-
tion and, in particular, coincides with differentiating epithe-
lium. For example, in day 14.5 p.c. embryos, differentiated
epithelial cells show strong lacZ transgene expression (i.e., oral
epithelia, olfactory epithelia, stomach wall, tooth primordia,
whisker follicles, and glandular epithelium). Similarly, in the
histiogenesis of the anterior pituitary derived from Rathke’s
pouch epithelium, MIEP-driven lacZ expression, which is
highly expressed in the anterior pituitary, is undetectable prior
to differentiation and proliferation of the epithelia of Rathke’s
pouch.
On the basis of these observations, we propose that the
MIEP-lacZ transgenic mouse system may be a useful animal
model system for dissecting viral tropism and developmental
expression of HCMV as determined by cellular transcription
factors interacting with the viral promoter. Further, this model
system may also be valuable in providing insight into the patho-
genesis of congenital HCMV infection. For example, HCMV
TABLE 1. Expression driven by MIEP (2670/154) compared with that of MIEP(2525/113) of Koedood et al. (23)
in transgenic mice at different embryonic stages
Organ and cell type
Transgene expression at day p.c.
8.5 10.5 11.5 14.5
#1a #2a Reference 23 #1 #2 Reference 23 #1 #2 Reference 23 #1 #2 Reference 23b
Primary germinal layer
Ectodermal cells 1 1 1 NAc NA NA NA NA NA NA NA NA
Endodermal cells 2 2 2 NA NA NA NA NA NA NA NA NA
Mesodermal cells 2 2 2 NA NA NA NA NA NA NA NA NA
Nervous tissue
Neurons of the spinal cord NDd ND ND 1 1 1 1 1 1 1 1 1
Diencephalon ND ND ND 1 1 1 1 1 1 2 2 NIe
Retina ND ND ND 1 1 1 1 1 1 2 2 1
Dorsal root ganglia ND ND ND 1 1 1 1 1 1 1 1 1
Meninges ND ND ND 1 1 1 1 1 1 2 2 2
Telencephalon ND ND ND 2 2 2 1 1 2 2 2 2
Inner ear epithelium ND ND ND 1 1 1 1 1 1 1 1 1
Trigeminal ganglia ND ND ND 1 1 1 1 1 1 1 1 1
Vestibulocochlear ganglion ND ND ND 1 1 1 1 1 1 1 1 1
Hindbrain ND ND ND 1 1 1 1 1 1 NA NA NA
Olfactory epithelium ND ND ND ND ND ND ND ND ND 1 1 1
Choroid plexus ND ND ND ND ND ND 1 1 1 1 1 1
Connective tissue
Lung mesenchymal cells ND ND ND 1 1 1 1 1 1 1 1 1
Heart region ND ND ND 1 1 1 1 1 1 1 1 1
Blood cells ND ND ND 1 1 NI 1 1 NI 1 2 NI
Dorsal mesentery ND ND ND 1 1 1 1 1 1 1 1 1
Esophagus ND ND ND ND ND ND 1 1 1 1 1 1
Tongue ND ND ND ND ND ND ND ND ND 1 1 2
Rib chondrocytes ND ND ND ND ND ND ND ND ND 1 1 NI
Epidermis ND ND ND ND ND ND ND ND ND 1 1 1
Striated muscle ND ND ND ND ND ND ND ND ND 1 1 2
Eye sclera ND ND ND 1 1 1 1 1 1 1 1 1
Endocrine tissue
Thyroid ND ND ND ND ND ND ND ND ND 1 1 2
Parathyroid ND ND ND ND ND ND ND ND ND 1 1 2
Pancreas ND ND ND ND ND ND ND ND ND 1 1 1
Submandibular gland ND ND ND ND ND ND ND ND ND 1 1 2
Rathke’s pouch ND ND ND 2 2 NI 2 2 NI NA NA NA
Pituitary ND ND ND ND ND ND ND ND ND 1 1 1
Other tissues
Adrenal ND ND ND ND ND ND ND ND ND 1 1 1
Kidney ND ND ND ND ND ND ND ND ND 1 1 1
Liver ND ND ND 1 1 1 1 1 1 1 1
Pharynx epithelium ND ND ND ND ND ND ND ND ND 1 1 1
Tooth primordia ND ND ND ND ND ND ND ND ND 1 1 1
Connective tissue, maxillary ND ND ND 1 1 1 1 1 1 NA NA NA
Branchial arches ND ND ND 1 1 1 1 1 1 NA NA NA
Endothelial cells —f — — 1 1 1 1 1 1 1 1 1
Mesothelial cells — — — 1 1 1 1 1 1 1 1 1
a Two independent transgenic mouse lines.
b Results in this column represent tissues positive at day 13.5 p.c. in reference 23.
c NA, not applicable at this stage.
d ND, tissues not developed at this stage.
e NI, not identified.
f—, embryos examined in situ only.
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FIG. 6. Day 14.5 p.c. embryo. (A) Longitudinal section of day 14.5 p.c. MIEP transgenic mouse embryo. lv, liver. Bar, 1 mm. (B) Choroid plexus (cp) of the 4th
ventricle (IV) and adjacent cerebellum (ce), showing highly b-galactosidase-positive cells in the choroid plexus. Bar, 250 mm. (C) b-galactosidase-positive olfactory epi-
thelium (ol). Bar, 500 mm. (D) Positive cells in the intermediate lobe (il) and anterior lobe (al) of the pituitary gland and the buccal epithelial lining (bu). Bar, 500mm. (E)
Tongue, with b-galactosidase-positive striated muscle (arrow). Bar, 100 mm. (F) Lower jaw, with b-galactosidase-positive tooth primordium (to). Bar, 100 mm. (G)
b-Galactosidase-positive pulmonary epithelial cells (arrows) and pulmonary capillaries (pc). Bar, 100mm. (H) Highly positive cells in the thyroid (th) and parathyroid (pt). Bar,
10 mm. (I) Positive chondrocytes in the rib (rb). Bar, 50 mm. (J) Positive blood cells in the ventricle (ve) of the heart. Note the absence ofb-galactosidase activity in the
epicardium (ec) and myocardium (mc). Bar, 500 mm. (K) Enlargement of ventricular area from panel J, showing positive blood cells within the ventricle. Bar, 100 mm.
(L) Positive endothelial cells lining the brain capillary. Bar, 50 mm. (M) Positive cells in the adrenal gland (ad). Bar, 250 mm. (N) b-Galactosidase-positive cells lining
the glomeruli (gl) in the kidney. Bar, 100 mm. (O) Positive hepatocytes in the liver. Bar, 100 mm. (P) b-Galactosidase-positive cells in the pancreas (pa). Bar, 100 mm.
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microgyria is a common feature in the brain pathology of
congenitally infected human infants (7) and has been postu-
lated to result from insufficiency of cerebral blood supply
rather than direct viral disturbance of neurogenesis or gliogen-
esis (9). The potency of transgene expression in brain vascu-
lature suggests a role for HCMV in perturbing angiogenesis
and blood-brain barrier function, thus providing a causative
link between HCMV and ischemia. Another example is pro-
vided by the pattern of transgene expression in extraembryonic
tissues, which suggests two potential modes of HCMV infec-
tion during fetal development. One mode is suggested by lacZ
expression in precursor placental cells. These cells may serve as
a vehicle for replicating virus to pass from the endometrium,
infect the umbilical endothelium, and disseminate to the em-
bryo (3). MIEP expression in the amnion indicates another
possible mode of transmission. Here, free virus or infected
amniotic cells may shed into the amniotic fluid as the devel-
oping fetus begins to imbibe surrounding fluid.
The observation of MIEP-lacZ expression in subpopulations
of cells in the various differentiated organ systems is particu-
larly intriguing. For example, only a subset of muscle cells
within the tongue and chrondrocytes in the rib were found to
express lacZ without any obvious difference from their nonex-
pressing neighbors. It is likely that prior developmental events
limit which cells permit MIEP activation. At one level, epige-
netic control via methylation of DNA or via position effect
variegation may lead to cell-specific restriction. Alternatively,
this restriction may operate by providing a cellular repressor to
the MIEP (35) or by limiting the population of cells which
express a positive transcription factor (12). In addition, extra-
cellular signals that regulate transcription factor activity could
affect one or more of these processes. In this connection, we
note that the pattern of transgene expression overlaps with
many sites in the embryo that express the RAR and RXR
subfamilies and which likely use retinoic acid for their growth
and differentiation (10, 32, 33). In particular, the differentia-
tion of epithelial cells (such as those in the developing teeth,
whisker follicles, lung, salivary glands, skin, chondrocytes, and
oral cavity) strongly correlates with expression of the gamma
subtype retinoic acid receptor (33) and is consistent with the
notion that HCMV may opportunistically use the retinoid sig-
naling pathway for activation (1, 11). Indeed, the MIEP con-
tains multiple signal-regulated elements, including an array of
NF-kB, ATF, AP-1, and retinoid receptor (RAR/RXR) bind-
ing sites (6, 11, 20, 28, 34, 38), which likely accounts for the
apparent promiscuous activity of the promoter in transient
transfection assays because of an elevated activation state un-
der conditions of in vitro cell culture. However, in vivo it is
possible that cell-specific combinatorial interactions among
these sites may modify transcription factor activity and inte-
grate signal inputs from different signaling pathways, thereby
affecting whether a signal-regulated transcription factor, in a
given cell, activates or represses transcription. Moreover, the
presence of signal-regulated elements in the MIEP is likely to
lead to restrictions that may also exist at levels other than
transcription. These restrictions might operate within a signal
transduction pathway.
Another possible mechanism for restricted expression within
defined cell populations may involve migratory components
with different origins. For instance, neuronal cells of the tri-
geminal ganglion are derived from two distinct migratory com-
ponents which originate from the epibranchial placodes and
FIG. 7. Extraembryonic structures. (A) Positive cells lining the umbilical vein (uv) from a 10.5 day p.c. transgenic embryo; note that the placenta (pl) is negative.
Bar, 250 mm. (B) b-Galactosidase-positive precursor placental cells in the ectoplacental cone (epc) of a 7.5 day p.c. transgenic embryo. Note that the embryo (em) and
decidua (de) are negative. Bar, 50 mm. (C) Day 15.4 p.c. transgenic embryo surrounded by amnion. Note the sporatic positive cells in the amnion. Bar, 2 mm. (D) Yolk
sac dissected from a day 14.5 p.c. transgenic mouse embryo. Note cells positive for b-galactosidase expression. Bar, 1 mm.
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neural crest cells in the day 8.5 to 9.0 p.c. embryo (8). Indeed,
MIEP expression is apparent in neural crest-derived cells at
day 8.5 p.c., but not in epibranchial placodes, and expression is
highly restricted to a specific subpopulation of trigeminal gan-
glion cells in day 10.5 embryos, perhaps signifying a cell lineage
marker for those cells. All these possibilities and perhaps oth-
ers are likely to determine the final level of tissue-specific
MIEP expression. The transgenic model provides a means to
test these possibilities, which will be the subject of future in-
vestigations.
In an earlier report (24), it was shown that an HCMVMIEP
segment from nucleotides2302 to172 was tightly regulated in
a cell-specific manner in embryos from transgenic mice. The
study by Kothary et al. (24) indicates that the 2302 to 172
segment of the MIEP is sufficient for initial activation at day
8.0 to 8.5 p.c. and later on for directing expression in the spinal
and sensory ganglia, choroid plexus, muscle, and a subset of
endothelial cells. More recently, a similar study by Koedood et
al. (23) was reported in which an enhancer-containing segment
(nucleotides 2525 to 113) of the MIEP was investigated for
embryonic expression. In line with our results, these investiga-
tors detected a similar expression pattern (for a comparison
between the two studies see Table 1). Although all sites of
expression detected by Koedood et al. are positive for the
MIEP(2670/154) transgene, significant differences involving
new sites of expression are noted in the present study. These
marked exceptions include the thyroid and parathyroid glands,
salivary glands, and striated muscle in day 14.5 p.c. embryos,
indicating that additional sequences outside the major en-
hancer segment (i.e., those sequences located from nucleotides
2670 to 2525 and 113 to 154) may contribute to tissue-
specific expression. We infer, based on a comparative analysis
of our results with those of Kothary et al. (24) and Koedood et
al. (23), that the2670 to2525 segment is required for efficient
glandular expression (in particular, thyroid, parathyroid, and
salivary glands), whereas the 113 to 154 segment is important
for expression in muscle. Note, the two previous studies did not
examine expression in blood cells, chondrocytes, and, most
importantly, in extraembryonic structures. Overall, our find-
ings together with those of Koedood et al. (23) strongly indi-
cate that the HCMV MIEP is a critical control point for de-
termining viral tropism in vivo. In the embryo, two phases of
transgene expression are exhibited. The first phase occurs dur-
ing body plan formation which subsequently becomes highly
restricted in the second phase upon differentiation of various
organ systems. How other regions surrounding the promoter,
in particular the modulator region (27, 35), affect promoter
activity remains open. However, the promoter segment studied
here is sufficient for recapitulating more fully the natural in-
fection pattern by HCMV in neonates.
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